Hypertension and Heart Failure: Epidemiology, Mechanisms and Treatment

ISBN-13: 9783031393143 / Angielski

Maria Dorobantu; Victor Voicu; Guido Grassi

Spis treści

Part I Epidemiology of hypertension and hypertensive heart disease.Prevalence and Risk of Heart Failure in Pre-Hypertensive and Hypertensive Patients.-Socio-economic burden of Heart Failure in hypertension.-Heart failure in hypertensive patients across the age spectrum.- PART II. MECHANISMS OF HEART FAILURE IN ARTERIAL HYPERTENSION.- Genetics and epigenetics in the progression from hypertension to heart failure.-.Hypertension and heart failure – the role of heart rate.-6.       Role of short and long-term blood pressure variability in relation to heart failure.-Hemodynamic markers in the progression from hypertension to heart failure.-Sympathetic Activity in Hypertension and Heart Failure.-Renal and Heart Failure interrelationship in Hypertension.-The role of uric acid – in hypertension and heart failure.-Myocardial ischaemia – a link between hypertension and heart failure.-Role of central blood pressure and arterial stiffening in heart failure.-Role of endothelial dysfunction in the progression from hypertension to heart failure.-Panendothelitis due to SARS-CoV2 infection – consequences on hypertension and heart failure.-Pathophysiology of Hypertensive Heart Disease.-Part III New perspectives on diagnosis of heart failure in hypertensive patients. Left ventricular diastolic dysfunction.-New perspectives imaging approaches in hypertensive patients with heart failure.-Cardiac biomarkers in the progression to heart failure in Hypertension.-Natriuretic peptides in the progression to heart failure in hypertensive patients.-Part IV Arrhythmic complications of hypertensive heart disease. Atrial fibrillation, hypertension and heart failure.-Ventricular arrhythmias, Hypertension and heart failure.-Part V Treatment of heart failure in hypertensive patients. Treating hypertension complicated with heart failure: going beyond the numbers.-Reversibility of cardiac remodelling in hypertensive patients with heart failure.-New antidiabetic agents for the treatment of heart failure in hypertensive patients.-Non-pharmacological treatment in hypertensive patients with heart failure.-RAAS blockers for the treatment of hypertension and heart failure.-The Role of Drug Therapy in Lowering Mortality and Morbidity: From High-Risk Hypertension to Established Heart Failure. Update.-Unmet Needs in drug treatment of Heart Failure in Hypertension.-Device-based treatment in hypertension and heart failure.-Renal denervation – for the prevention of heart failure in hypertensive patients.- Smart technologies for improving heart failure in hypertensive patients.-Part VI Special populations. Hypertension and heart failure in the young adult.-Heart Failure with Preserved Ejection Fraction – Current Management and Future Strategies pre-Heart Failure.-Hypertension and heart failure in pregnancy.-Hypertension and Heart Failure in cancer patients.-Hypertension and heart failure in post-COVID patients.-Heart Failure in Hypertensive patients –is it time to change the guidelines?

O autorze

Maria Dorobantu is Professor of Cardiology at the University of Medicine and Pharmacy Carol Davila Bucharest, Romania. She has a special interest in the assessment and treatment of heart failure and arterial hypertension and has been principal investigator of important trials. She is the President of the Romanian Society of Hypertension and the national coordinator of the SEPHAR studies (Study for the Evaluation of Prevalence of Hypertension and Cardiovascular Risk among the Adult Population of Romania). Between 2016-2018 she has been the chairperson of the Coronary Pathophysiology and Microcirculation Working Group of Europeam Society of Cardiology. 
Giuseppe Mancia is Professor Emeritus of the University of Milano and Head of the Hypertension Centre of the Instituto Clinico Universitario, Verano Brianza. He is President of the Italian Foundation on “Ricerca e Innovazione su Ipertensione e Protezione Cardiovascolare”, of the Foundation of the European Society of Hypertension (ESH) in Zurich and Chairman of the Educational Board of ESH.
He is since many years in the list of the “highly cited” scientists (Thompson Reuters) and has in 2013 been regarded as one of the 400 most influential biomedical investigators in the world (EJCI 2013).
Guido Grassi is Professor of Internal Medicine at the Dept. of Clinical Medicine of the University of Milano, director of the PhD course in "Hypertension and Cardiovascular Risk", and director of the Center of Clinical Physiology and Hypertension of the same university.
He is member of the Scientific Council on Hypertension of the ESC, ESH and ISH. He is also member of the ESH/ESC Task   Force Guidelines on the Management of Hypertension.
He is Executive Editor of “Journal of Hypertension”, official Journal of the ISH and the ESH.
Victor Voicu is currently fellow the and vice president of Romanian Academy and President of Medical Science Section of Romanian Academy. He is Professor of Department of Pharmacology, Toxicology and Clinical Psychopharmacology, Faculty of Medicine, University of Medicine and Pharmacy “Carol Davila” Bucharest. He is President of the Romanian Society of Therapeutics, Pharmacology and Clinical Toxicology, and coordinator of Drug Sciences Panel of the Executive Unit for Financing of Higher Education, Research, Development and Innovation (EUFHERDI). Prof. Voicu is correspondent member from abroad  of French National Academy of Medicine.

Blurb

This book explains how hypertension affects 20-50% of the adult population in developed countries. Heart failure is the result of the hypertension's effects on the heart and it represents a growing public health problem.
In this context the international scientific community is continuously struggling to develop better strategies in screening, diagnosing and treating hypertension and its deleterious effects. Thus, this field is continuously changing, with new important information being added constantly. This book will offer both insights into the intimate mechanisms of transition from hypertension to heart failure and clinical practice advice on the prevention and treatment of heart failure in hypertensive population. The second edition will dedicate new chapters regarding the socio-economic burden of hypertension and the role of heart rate, endothelial dysfunction and uric acid in the progression from hypertension to heart failure. A part of the book will be dedicated to diagnostics, comprising a chapter on new perspectives on multimodality imaging and a special chapter on diastolic dysfunction. The arrhythmic complications of hypertensive heart disease will be structured in 2 chapters on atrial fibrillation and ventricular arrhythmias respectively. New chapters will be added regarding hypertension and heart failure in special populations such as cancer patients, young patients, pregnancy and patients with a history of SARS-CoV2 infection.